LMR Partners’s Monte Rosa Therapeutics GLUE Stock Holding History

LMR Partners’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-58,500	Closed	-$1.33M	–	1073
2021 Q2	$1.33M	Buy	+58,500	New	+$1.19M	0.02%	460

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LMR Partners's GLUE Position: Q3 2021 in Review

LMR Partners sold out of Monte Rosa Therapeutics (GLUE) in Q3 2021, closing a stake of 58,500 shares — an estimated $1.33M sold.

LMR Partners first reported a position in GLUE in Q2 2021 and held it in 1 quarter. The position peaked at $1.33M in Q2 2021. 56 funds tracked by Wall St. Rank hold GLUE as of Q3 2021.

LMR Partners reported no remaining Monte Rosa Therapeutics position as of Q3 2021 after selling out during the quarter.
LMR Partners sold 58,500 Monte Rosa Therapeutics shares in Q3 2021, an estimated $1.33M.
LMR Partners first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 1 quarter.
LMR Partners's Monte Rosa Therapeutics position peaked at $1.33M in Q2 2021.
56 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2021.

Based on LMR Partners's 13F filing for Q3 2021, filed 15 Nov 2021.